Navigation Links
Two Metabolex Projects Recognized in Windhover's Top 10 Lists for Partnering Opportunities
Date:11/3/2008

HAYWARD, Calif., Nov. 3 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that two of its programs (MBX-2982 and MBX-8025) have been recognized in Windhover's "Top 10 most interesting projects available for partnering" in their respective categories. MBX-2982, a potential first-in-class treatment for type 2 diabetes, was recognized in the metabolic category and MBX-8025, a potential treatment for a range of dyslipidemias, was recognized in the cardiovascular category. The selections were made by independent committees assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology and medical device industries.

"We are honored to receive this significant recognition for not one, but two of our current programs. This recognition underscores both MBX-2982's potential to become an important new therapy for type 2 diabetes, and MBX-8025's potential in the treatment of dyslipidemia," said Harold Van Wart, Ph.D., Chief Executive Officer of Metabolex.

The metabolic selection committee was led by Marc Wortman, contributing writer to Windhover's IN VIVO and Start-Up, and Harris Kaplan, President & CEO, and Jun Huangpu, Managing Director, of Healogix, a leading business development strategy consulting firm. The cardiovascular selection committee was led by Ed Saltzman, President, and Michael Rice, Senior Consultant, of Defined Health, a leading business development strategy consulting firm.

Drawing on the analytic resources of these organizations, the selection committees evaluated hundreds of compounds currently in development.

"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees considered the most attractive metabolic and cardiovascular opportunities the industry has to offer," said Roger Longman, Managing Director of Windhover Information. "Winners have met rigorous criteria including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability."

Metabolex plans to present information on MBX-2982 and MBX-8025 on November 4, 2008 at Windhover's Therapeutic Area Partnerships conference in Philadelphia, PA.

MBX-2982

MBX-2982 is an agonist of GPR119, a G protein-coupled receptor that is expressed in pancreatic islets and the gastrointestinal tract. Pre-clinical studies conducted by Metabolex and others show that GPR119 agonists can stimulate glucose-dependent insulin secretion and release of incretin hormones such as GLP-1, and thus may preserve beta cell health. This novel dual mechanism may provide a unique therapeutic benefit in the treatment of type 2 diabetes. Additionally, the stimulation of GLP-1 release may mimic the benefits of incretin analogues such as exenatide (a GLP-1 analogue marketed as Byetta(R)). Unlike exenatide, however, MBX-2982 can be delivered orally.

MBX-8025

MBX-8025 is a potent, selective PPAR-delta agonist that helps to regulate fatty acid degradation, lipid storage/transport and insulin sensitivity. MBX- 8025 is being developed to treat a range of dyslipidemias, and early research suggests it may have a broader effect on a number of lipid and metabolic parameters, including triglycerides, LDL and HDL cholesterol, insulin sensitivity and inflammation.

About Windhover

Windhover Information Inc., an Elsevier company, has provided analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO, The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and webinars. For more on the company's products and services, please see http://www.windhover.com.

About Metabolex

Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. The company has four clinical-stage compounds: MBX-102/JNJ 39659100, which has completed three Phase 2 trials; MBX-2044, which has completed a Phase 2a trial; MBX-8025, which recently completed a Phase 2 trial in patients with dyslipidemia; and MBX-2982, which recently completed a Phase 1 trial. Ortho-McNeil, Inc. has the exclusive right to develop and commercialize MBX-102/JNJ 39659100. For additional information about Metabolex and its development pipeline, visit http://www.metabolex.com.


'/>"/>
SOURCE Metabolex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Metabolex Names Zhao, Martin to Executive Posts
2. Metabolex Appoints Donald Hill as Chief Financial Officer
3. Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinsons Disease
4. China Pharma Holdings, Inc. Projects 3rd Quarter 2008 Revenue Growth to Exceed 40%
5. Maryland Stem Cell Research Commission Recommends 62 Projects for Funding
6. JIC Invests in Three New Alternative Energy Projects
7. China Biologic Products Announces One of Its R&D Projects Has Been Listed In National Torch Plan
8. Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord
9. Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
10. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
11. BioTrends Research Group, Inc. Recognized as One of Philadelphias Fastest Growing Privately Held Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking ... Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity as ...
Breaking Biology Technology:
(Date:6/22/2016)... WASHINGTON , June 22, 2016 On ... highly-anticipated call to industry to share solutions for the ... by U.S. Customs and Border Protection (CBP), explains that ... nationals are departing the United States ... criminals, and to defeat imposters. Logo - ...
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
Breaking Biology News(10 mins):